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Diabetes: Is There a Future for 
Pharmacogenomics Guided Treatment? 
Ewan R. Pearson1,*
Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of diabetes where defining 
the genetic cause has a dramatic impact on treatment—with patients being able to transition from insulin to 
sulfonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued 
to date for pharmacogenetics of metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase- 4 inhibitors 
but highlights that these variants will only be of clinical utility when the genotype is already known at the point of 
prescribing. The future of pharmacogenetics in diabetes and other common complex disease relies on a paradigm 
shift—that of preemptive panel genotyping and use of clinical decision support tools to assimilate this genetic 
information with other clinical phenotypic data and to present this information simply to the prescriber. Given the 
recent dramatic fall in genotyping costs, this future is not far off.
To date, clinically actionable pharmacogenomics has largely been 
limited to severe idiosyncratic adverse drug reactions, to variation 
in drug metabolism, and to treatment outcome in cancer che-
motherapeutics where the somatic mutations drive the choice of 
targeted intervention. In this review, I will focus on pharmacog-
enomics in type 2 diabetes and use this not only to outline the 
recent advances in the field but to address the challenges that are 
faced when considering genetics of treatment efficacy and (usually 
mild–moderate) side effects in common complex disease.
THE COMPLEX ETIOLOGY OF DIABETES
Diabetes, like many complex diseases, is diagnosed based upon a 
threshold being achieved in a normally distributed trait. In the 
case of diabetes, this is a fasting blood glucose >7 mmol/L with the 
threshold level being that at which the risk of microvascular com-
plications emerges. There are many reasons why an individual’s 
blood glucose can rise above this threshold; however, traditionally 
two groups are identified—type 1 and type 2 diabetes. Whilst 
type 1 diabetes has a clear etiology (autoimmune islet beta- cell de-
struction), type 2 diabetes is essentially a diagnosis of exclusion—
it is what is left after all other known causes are ruled out. Thus, it 
seems likely that within this categorical bin that is type 2 diabetes 
there may well be definable subgroups of distinct etiology. Over 
the last 20 years, an increasing number of monogenic forms of di-
abetes have been identified, which are often still mistaken for type 
2 diabetes. As will be outlined later, these monogenic forms of di-
abetes can have extreme response to targeted diabetes treatments 
and represent robust exemplars for pharmacogenomics in the di-
abetes clinic. However, whilst it is tempting to assume that as we 
gain more knowledge of diabetes etiology we will slice the group 
with type 2 diabetes into discrete subtypes, we need to recognize 
that true type 2 diabetes is indeed a polygenic disease. Recent ge-
netic studies have established that there are likely thousands of 
common risk variants that contribute to type 2 diabetes risk, and 
the contribution of rare or low frequency variants, whilst individ-
ually of large effect, do not contribute greatly to the overall preva-
lence of type 2 diabetes.1
TREATMENT RESPONSE IN TYPE 2 DIABETES
Traditionally pharmacogenomics of drug efficacy is divided into 
variants that alter drug pharmacokinetics (PK), and variants that 
alter drug pharmacodynamics (PD) (Figure 1). In the context of 
a complex disease such as type 2 diabetes where there is consider-
able etiological variation, it is helpful to divide PD variation into 
differences in drug response that reflect the underlying etiological 
variation and differences that do not. Most diabetes drugs act to 
attempt to reverse the pathophysiological (etiological) defects that 
contribute to the development of diabetes and thus differences in 
etiology (e.g., beta- cell failure) are likely to impact on response to 
drugs that primarily work on this pathway (e.g., sulfonylureas). 
As such we would anticipate that understanding the genetic eti-
ology of diabetes should translate to pharmacogenomics of that 
drug/etiological pathway. Conversely, as will be described later for 
metformin, understanding genetic architecture of diabetes drug 
response may provide insights into diabetes etiology. By contrast, 
some drugs (e.g., sodium glucose transporter 2 inhibitors) lower 
blood glucose via a distinct mechanism (in this case inhibiting glu-
cose reabsorption resulting in glycosuria) that is not etiological for 
diabetes, and therefore in this scenario, genetic variation in etiol-
ogy is unlikely to map to variation in drug response.
SMALL PHARMACOGENETIC EFFECTS ARE ACTIONABLE 
IF GENOTYPE IS FREE AND AVAILABLE AT THE POINT OF 
PRESCRIBING
Diabetes drugs vary in their efficacy by class. Metformin and sul-
fonylureas are probably the most potent, with hemoglobin A1c 
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(HBA1c) reduction of 1–1.5% often seen with dipeptidyl pepti-
dase-4 (DPP- 4) inhibitors achieving a mean HbA1c reduction 
of ~ 0.6%. At this point, for the nondiabetes audience, it should 
be noted that glycemia is measured as an absolute measure of 
percentage- glycated hemoglobin. Thus, absolute change in HbA1c 
can be mistaken to be a relative change—a 1% improvement in 
HbA1c is a robust effect, not a trivial effect, and is associated with 
a ~ 30–40% reduction in risk of microvascular complications. In 
clinical trials a difference between interventions of 0.3% is consid-
ered to be a clinically important difference.
Given that pharmacogenetic effects of diabetes drug treatment 
are likely to reflect the underlying etiology (Figure 1) and that true 
type 2 diabetes is highly polygenic, consisting of multiple small- 
effect etiological variants, it is likely that for treatment efficacy the 
pharmacogenetic effects will be small. We have shown this to be 
the case for metformin response, where the heritability is spread 
evenly across all the chromosomes, rather than being driven by a 
few loci of large effect.2 The exception to this are the large effects 
seen in monogenic diabetes or the modest effects seen for drug 
intolerance.
The traditional approach to pharmacogenomics is to request 
a genetic test before issuing a prescription. This works where the 
risk of harm is high (e.g., severe adverse drug reaction) or the risk 
of nonefficacy is high (e.g., chemotherapy) compounded by the 
high cost of the drug. Yet in type 2 diabetes, where pharmacoge-
netic effects are likely to be small and drug costs are also relatively 
small, a clinician or healthcare provider is unlikely to sanction the 
cost of genotyping/sequencing and the time taken to get the re-
sult before deciding on diabetes drug choice. However, the cost of 
sequencing and genotype arrays is falling dramatically. Now it is 
possible to undertake genome- wide genotyping, with high-density 
imputation for ~ £30/$40. Most but not all absorption, distribu-
tion, metabolism, excretion (ADME) content is captured as would 
be other variants associated with drug efficacy. At this price, pre-
emptive genotyping with actionable genotypes embedded in the 
medical record has the potential to be a reality. With appropriate 
information technology infrastructure and mapping of genotype 
to a clear clinical action, the genotyping information would be free 
and instantly available at the point of prescribing, embedded in a 
clinical decision support tool. At this point the genotype will be-
come as easy to use to guide decisions as body mass index or sex. At 
this point, small to modest pharmacogenetic effects can be used to 
guide prescribing—if a decision between two diabetes treatments 
is in equipoise, the genetic information can help steer the decision.
This paradigm shift represents a challenge for healthcare pro-
viders and payers. The current approach to implementation of new 
treatments or diagnostics requires evidence of efficacy and cost 
effectiveness, often in the form of a clinical trial. Yet for pharma-
cogenetics the potential combinations of drug–gene interactions 
are many, and it would be unfeasible for every combination to be 
tested in an outcome trial. It is more realistic to ensure that as long 
as there is a sufficient level of evidence to support the introduction 
of pharmacogenetic- guided prescribing, there is a rigorous evalu-
ation of outcomes to enable a full assessment of effectiveness and 
cost- effectiveness post hoc.
PHARMACOGENOMICS IN COMMON COMPLEX DISEASE—
PROBABILISTIC RATHER THAN DEFINITIVE OUTCOMES
One final concept that applies to pharmacogenomics of common 
complex diseases like type 2 diabetes is that the genetics are not 
likely to be used to give a definitive prediction. So, for example, 
when prescribed abacavir, if an individual has the HLA- B*5701 
genotype, then the evidence is clear—they should not receive ab-
acavir.3 In type 2 diabetes this is unlikely to ever be the case. In 
part this is because the effect size is likely to be small (as already 
discussed) and, importantly, because the response trait is highly 
variable within individuals. Thus, whilst on average a group of pa-
tients carrying a “good response” allele will respond better than a 
group who don’t carry this allele, at an individual level there will be 
some who carry the good response allele who respond poorly; sim-
ilarly there will be individuals who do not carry the good response 
allele who respond well. Therefore, we cannot predict with any 
degree of certainty unless the predicted allelic effect is very large 
(which, other than in monogenic diabetes, it isn’t). Therefore, gen-
otype will be used in combination with clinical characteristics to 
develop a probabilistic response prediction (Figure 2), where, for 
Figure 1 A framework for evaluating PGx in type 2 diabetes. PGx, pharmacogenetics; SGLT2i, sodium glucose transporter 2 inhibitor.
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example, a patient is predicted to have a 73% probability of achiev-
ing a target HbA1c with one drug but only a 50% probability with 
an alternative drug. In this scenario, this information on proba-
bility of response can be used by the doctor and patient to decide 
on what treatment should be prescribed, weighing up the charac-
teristics of the drug, potential side effects, and patient preference.
DRUG RESPONSE IN DIABETES—THE CLINICAL 
PHENOTYPE
Before moving to examples of how genetic variation has been 
established to alter drug response in diabetes, it is important to 
recognize that genetic variation is only one aspect to be considered 
in predicting the efficacy of a diabetes drug. Traditionally clinical 
trials did not consider patient phenotype when evaluating drug 
response. However, recent studies have revisited these trials and 
shown that even simple parameters like body mass index and sex 
matter. For example, obese women respond very well to thiazo-
lidinediones, whereas slim men respond well to sulfonylureas.4 
With more systematic evaluation of phenotype and incorporat-
ing measures of insulin resistance and beta- cell function, patients 
with diabetes have been divided into five groups or subtypes.5 It is 
likely that these groups will respond differently to diabetes treat-
ments. In this context, genetic variation will need to be considered 
layered upon such clinical and physiological variation in order to 
guide treatment choice.
MONOGENIC DIABETES—PHARMACOGENOMIC- GUIDED 
TREATMENT IS ALREADY PART OF CLINICAL PRACTICE
As has been mentioned, monogenic diabetes represents the excep-
tion to the concepts outlined above. The term monogenic diabetes 
covers all forms of diabetes caused by a single-point mutation or 
deletion in or of a gene. There are many rare forms of monogenic 
diabetes that are beyond the scope of this review. Here, I will focus 
on the monogenic beta- cell disorders that cause maturity onset di-
abetes of the young (MODY) and the rare beta- cell disorders that 
cause neonatal diabetes, as these genetic subtypes can be treated 
differently from “normal” type 1 or type 2 diabetes.
MODY is itself a heterogeneous condition with domi-
nant mutations in more than  10 genes found to be causal (for 
more information see ref. 6). MODY traditionally presents as 
non–insulin- requiring diabetes with onset before the age of 
25  years, with a three- generation family history. The most com-
mon form of MODY is caused by mutations in the gene, HNF1A, 
encoding the transcription factor hepatocyte nuclear factor 1α. 
Because HNF1A MODY often presents at a young age it may 
be mistaken for type 1 diabetes; or, as it can present at a later age 
without insulin requirement, it can be mistaken for type 2 diabetes. 
However, unlike type 2 diabetes, this genetically defined subgroup 
is exquisitely sensitive to sulfonylurea treatment. A randomized 
crossover trial of metformin and gliclazide (a sulfonylurea) in pa-
tients with type 2 diabetes and with HNF1A MODY established 
that the MODY patients were fivefold more sensitive to the glucose- 
lowering effects of sulfonylureas than patients with type 2  diabetes.7 
This finding led to successful transition of patients (who had been 
incorrectly diagnosed as having type 1 diabetes) from insulin treat-
ment to low-dose sulfonylurea, often after many years of being 
labeled insulin dependent.8 The pharmacogenetic effect size here 
is so large that knowing an individual’s genotype will prompt de-
finitive treatment advice—use a low-dose sulfonylurea. However, 
the caveat is that as MODY is rare (~ 3% of diabetes diagnosed 
Figure 2 The future of pharmacogenetics in type 2 diabetes—incorporating genotype into a clinical decision support tool. A primary care 
physician starts to prescribe a new treatment for a patient whose glycemic control is above target. A clinical decision support tool built into 
the prescribing tool queries simple clinical and laboratory measures, actionable genotypes, and other biomarkers. The output is a probability 
of likely response and likely adverse drug reaction (ADR). The physician can use this to guide a discussion with their patient about the best 
drug to initiate to maximize benefit and minimize harm. BMI, body mass index; HbA1c, glycated hemoglobin A1c; SU, sulfonylurea; WGS, 
whole-genome sequence. 
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less than 30 years of age) there is no logic in testing for MODY in 
every patient thought to have type 2 diabetes before prescribing a 
sulfonylurea as most won’t have MODY, and many patients with 
type 2 diabetes will respond well to sulfonylureas anyway.
Another form of MODY is caused by a genetic defect in glucoki-
nase, the pancreatic glucose sensor. This presents as mild fasting 
hyperglycemia present from birth but with relatively normal post-
prandial glucose rise and HbA1c, and as a result with no long- term 
increased risk of microvascular complications.9 However, if a child 
is tested (for another reason) and found to have raised blood glu-
cose, they are often assumed to have type 1 diabetes and started on 
insulin treatment. Interestingly, insulin treatment makes no differ-
ence to the level of HbA1c,10 and no diabetes treatment is required 
in people with Glucokinase- MODY. As a result, patients misdiag-
nosed as having type 1 diabetes can stop their insulin, and patients 
misdiagnosed with type 2 diabetes can stop all oral therapy.
Neonatal diabetes (NDM) is a form of diabetes that presents 
within the first 6 months of age. At this age, it is very difficult to ac-
quire an autoimmune type 1 diabetes and highly likely that there is 
a genetic etiology. Fifty percent of cases of NDM have been found 
to be caused by heterozygous mutations in the genes encoding the 
KATP channel subunits KIR6.2
11 and SUR1.12 These mutations re-
sult in the KATP channel being insensitive to intracellular adenosine 
triphosphatase (ATP) and therefore remaining open, holding the 
beta cell in a hyperpolarized state, and unresponsive to glucose.11 
The KATP channel is the site of action of sulfonylureas, which close 
the channel and promote insulin secretion. In these patients, sulfo-
nylureas used at high dose (2–4 times the maximum adult dose/kg) 
are able to close the mutant KATP channels and stimulate insulin 
secretion.11 This work led to the successful transition off lifelong 
insulin treatment onto sulfonylurea treatment in 90% of patients 
with NDM.13 Another striking example of pharmacogenomics.
PHARMACOGENOMICS IN TYPE 2 DIABETES
There are many studies reporting genetic impact on diabetes 
drug response in type 2 diabetes. These are often studies done 
in small numbers (e.g., 100 patients) and are not replicated. As 
the anticipated effect sizes are small in type 2 diabetes, it is likely 
that most of the reports in the literature are false positives. In 
this review I do not attempt to compile all the pharmacogenetic 
studies of diabetes drugs because there are a number of recent 
reviews that have done this.14–16 Instead I will focus on two key 
areas—pharmacogenetic effects that are robust (on the basis of 
replication and/or biological plausibility) and have the potential 
to translate into clinical care, and how pharmacogenetics can be 
used to provide insight into diabetes etiology and drug action, 
specifically in relation to metformin. I will focus on metformin, 
sulfonylureas, thiazolidinediones, and DPP- 4 inhibitors. There 
are only limited pharmacogenetic studies published for sodium 
glucose transporter 2 inhibitors and glucagon- like peptide- 1 re-
ceptor agonists.
METFORMIN EFFICACY
Metformin is the first- line drug treatment for type 2 diabetes. It is 
derived from the French lilac and has been in clinical use for over 
60 years. Yet its mechanism of action remains much debated—for 
an overview of its action see ref. 17. Metformin is a highly effective 
treatment that is associated with weight loss and probable cardio-
protection, and it is being investigated for its potentially beneficial 
effects on cancer risk and outcomes18 and aging.19 It should be 
noted, however, that metformin also causes quite considerable gas-
trointestinal (GI) side effects in ~ 10% of individuals who are pre-
scribed the drug, leading to cessation in ~ 5%. The mechanisms 
for GI intolerance are also poorly understood. The considerable 
benefits with confusion about mechanism of action and side ef-
fects makes this an intriguing drug worth studying!
In a novel approach to investigate metformin mechanism, a 
genome- wide association study (GWAS) was undertaken in pa-
tients with type 2 diabetes treated with metformin, with HbA1c 
reduction after initiation as the outcome. In the first study reported 
in 2011,20 the initial discovery GWAS was ~ 1,000 patients, with a 
total sample size of 4,200 patients. Here, we identified that a locus 
on chromosome 11 that includes the genes NPAT and ATM was 
associated with glycemic response to metformin. Subsequently, 
the Metformin Genetics Consortium (https ://www.pgrn.org/
metgen.html) was formed, and the available sample size was in-
creased to 12,910 patients, with the discovery that an intronic vari-
ant altering SLC2A2 (GLUT2) expression levels was associated 
with glycemic response to metformin.21 These two metformin 
loci (NPAT/ATM and SLC2A2) are the most robustly repli-
cated pharmacogenetic variants in type 2 diabetes. As with many 
genetic studies, they raise more questions than they answer. For 
the NPAT/ATM locus it is tricky to be sure of the causal variant 
and gene, and work is ongoing in mouse models to investigate the 
mechanism, but it is tempting to conclude that the cancer gene, 
ATM, is causal. Patients who carry recessive mutations in ATM 
develop ataxia telangiectasia, which is a condition characterized 
by ataxia, lymphoproliferative cancer, immunoglobulin deficiency, 
and diabetes and insulin resistance.22 SLC2A2 is a more plausible 
gene where variation can alter glycemic response to metformin, 
as this is the main glucose transporter in the liver and is involved 
in glucose transport in the gut, beta cell, and hypothalamus. The 
SLC2A2 single- nucleotide polymorphism rs8192675 is the top 
expression quantitative trait locus for GLUT2 in the liver, with 
the increased efficacy allele being associated with lower expres-
sion of GLUT2.21 The mechanism for how reduced expression of 
GLUT2 alters metformin action, and whether this relates to a liver 
effect or gut effect remains under investigation. The effect size 
for rs8192675 is not small: In obese individuals, there is a 0.33% 
greater HbA1c reduction in the 9% of white Americans who carry 
two copies of the C allele compared with those who carry two 
copies of the T allele.21 This is the equivalent of a difference in 
metformin dose of 550 mg, or over half the effect seen with the 
initiation of a DPP- 4 inhibitor. In black Americans, the good re-
sponse C allele is homozygous in 49% of the population, suggest-
ing that this genetic variant will have a large population effect on 
metformin response in this ethnic group. Will these genetic effects 
translate into clinical practice? The challenge is that metformin 
is a cheap, effective drug that is used first- line, and has benefits 
beyond glycemia (such as weight lowering and potential reduction 
in cancer risk), and it is therefore unlikely that it will displaced 
from its first line- position, even for those patients where it is likely 
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to be less effective. Studies need to be done to establish whether 
dose adjustment can compensate for the pharmacogenetic effect, 
enabling genotype- based dosing of metformin.
METFORMIN INTOLERANCE
Approximately 5–10% of patients cannot tolerate metformin, 
largely due to intestinal side effects (bloating, abdominal pains, 
and diarrhea). Metformin is a cation with low lipid solubility, re-
quiring its active transport across cell membranes by a variety of 
transporters, including the organic cation transporters. In the gut, 
metformin is predominantly absorbed in the small intestine, with 
~ 30% secreted unchanged in the feces. Metformin is highly con-
centrated in the enterocytes of the jejunum, with concentrations 
as high as 500 μg/g (30–300 times higher than seen in plasma). 
Many underlying mechanisms for GI intolerance to metformin 
have been postulated (reviewed in ref. 23): a direct effect of the 
high metformin concentration of metformin in the enterocytes 
where metformin acts as a cellular poison, alteration of the gut mi-
crobiome by metformin,24,25 alteration of serotonin or histamine 
uptake or metabolism, a reduction in bile acid reabsorption result-
ing in increased bile acid exposure to the colon.
Genetic studies of metformin intolerance have focused on the 
transport of metformin from the lumen into the enterocytes. The 
three main transporters for metformin expressed in human gut 
are organic cation transporter 1 (OCT1, encoded by SLC22A1), 
plasma membrane monoamine transporter (PMAT, encoded by 
SLC29A4), and serotonin transporter (encoded by SLC6A4). A 
recent study in mice suggests OCT3 (encoded by SLC22A3) may 
also play a role,26 but this has not yet been established in humans. 
Variants involving all three known human transporters have now 
been associated with increased intolerance to metformin. Initially, 
using the GoDARTS study, Dujic et  al.27 identified that carriers 
of reduced function variants in SLC22A1 (encoding OCT1) had 
increased risk of GI intolerance. GI intolerance in these studies 
is defined using a proxy phenotype of those who stop metformin 
within 6 months and switch to an alternative treatment. Figure 3 
shows that those with two reduced function SLC22A1 alleles had 
a more than twofold increase in the odds for metformin intoler-
ance (P < 0.001); this effect increased to over fourfold when pa-
tients were coprescribed drugs known to inhibit OCT1, such as 
omeprazole, tricyclic antidepressants, doxazosin, and verapamil.27 
Dujic followed up with a study of the serotonin receptor, show-
ing that the low- expressing S* variant in SLC6A4 was associated 
with increased intolerance (odds ratio (OR) 1.31, P  =  0.031), 
and there was an interaction between SLC6A4 genotype and 
SLC22A1 genotype, such that in patients with two reduced- 
function SLC22A1, variants, the L* alleles of SLC6A4, were as-
sociated with a ninefold increase risk of intolerance (OR 9.25, 
P < 10−4).28 Finally, recently Dawed et al. investigated metformin 
intolerance in the IMI- DIRECT consortium, where metformin 
intolerance was self- reported by patients, resulting in cessation 
of metformin or the inability to increase the dose beyond 1 g. 
This study investigated the third gut metformin transporter 
PMAT and established that the G- allele at rs3889348, associated 
with reduced PMAT expression in the gut, was associated with 
a 1.34 (P  =  0.005) increased odds of GI intolerance (https :// 
doi.org/10.1101/436980). When considered in the context of the 
SLC22A1 reduced-function variants and the described quantita-
tive trait locus for PMAT in the gut, the odds of intolerance were 
2.15 (95% confidence interval (CI), 1.2–4.12) in those carrying 
three or more risk alleles for these two genes. Given the likely api-
cal location of these transporters, intolerance is associated with re-
duced uptake into the enterocytes and therefore likely increased 
luminal metformin concentration in the gut. This suggests that 
metformin- induced intolerance is mediated via mechanisms medi-
ated from within the lumen, such as its impact on the microbiome, 
bile acids, or biogenic amines, rather than increased metformin 
concentration in the enterocytes.
SULFONYLUREA EFFICACY AND HYPOGLYCEMIA 
Sulfonylureas have been in clinical use for as long as metformin, 
yet unlike metformin, the main mechanism of action is well eluci-
dated. Sulfonylureas bind to the SUR moieties of the KATP chan-
nel, bringing about channel closure, membrane depolarization, 
and influx of calcium via voltage gated calcium channels, resulting 
in insulin secretion. Interestingly, despite this pathway being well 
characterized, there has been limited success in identifying can-
didate gene variants that alter glycemic response to sulfonylureas. 
The replicated findings are for variants in ABCC8/KCNJ11 that 
alters KATP channel function and for the diabetes risk variant in 
TCF7L2.
The E23K (rs5219) variant in KCNJ11 and S1369A (rs 
757110) variant in ABCC8 are tightly linked, with the K23/
A1369 haplotype being associated with risk for type 2 diabetes. 
Sulfonylureas differ in the way they interact with the KATP chan-
nel, and functional studies have established that this haplotype 
has a striking effect on efficacy of the different sulfonylureas.29 
Here, the KATP channels containing the K23/A1369 haplotype 
were more sensitive to inhibition (closure) by gliclazide but 
less sensitive to closure by tolbutamide, chlorpropamide, and 
Figure 3 The combined effect of reduced function SLC22A1 
genotypes and organic cation transporter 1 (OCT1) interacting 
drugs on likelihood of metformin intolerance. The reference is those 
individuals with 1 or 0 risk alleles (RAs) who are not treated with a 
potential interacting drug (+ drug). Carriage of more than one RA or 
the use of interacting drugs are associated with intolerance. There 
is an additive effect in those with more than one RA who are also 
treated with interacting drugs having the greatest risk of intolerance.
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glimepiride. The K23/A1369 haplotype had no impact on glip-
izide or glibenclamide action. This functional work translates, 
in part, to that observed in clinical studies. Three Chinese stud-
ies report that the K23/A1369 haplotype was associated with 
greater response to gliclazide.30–32 The largest of these was a 
prospective study of 1,268 patients with type 2 diabetes, treated 
with gliclazide for 8  weeks. Those homozygous for the K23/
A1369 haplotype had a small but significantly greater reduc-
tion in fasting glucose, 2-hour glucose, and HbA1c compared 
with those with the E23/S1369 haplotype.31 Other studies do 
not show an association of the K23/A1369 haplotype with sul-
fonylurea response, potentially reflecting lack of power of the 
different sulfonylureas used. For example, the UKPDS study 
(where chlorpropamide and glibenclamide were the two sulfo-
nylureas used) showed no impact of this haplotype on fasting 
plasma glucose change at 1 year in 363 patients randomized to 
sulfonylurea.33 This could be explained by the predicted lack of 
genotype effect on glibenclamide response masking any reduced 
efficacy predicted for chlorpropamide response.
The diabetes risk variant rs7903146, an intronic single- 
nucleotide polymorphism within the TCF7L2 gene has the largest 
genetic effect on population risk for diabetes to date.34 This risk 
variant is associated with reduced beta- cell function and is thus a 
plausible candidate for altering glycemic response to sulfonylureas. 
In the population- based GoDARTS study, patients with type 2 
diabetes homozygous for rs1225372 (in close linkage disequilib-
rium  with rs7903146) were more likely not to achieve a treatment 
HbA1c < 7%, (OR 2.16 (1.121–3.86), P = 0.009) than patients 
with no risk variant. This result has been replicated in two inde-
pendent studies.35,36 A recent study, SUGAR- MGH, evaluated the 
effect of the diabetes risk variant rs7903146 on response to single- 
dose glipizide and 2 days of metformin.37 They show that the risk 
variant is associated with increased glucose lowering with glipizide 
and increased glucose lowering with metformin. Whether this re-
flects acute vs. chronic dosing or biases in the observational data 
previously reported, there remains some uncertainty over the im-
pact of TCF7L2 variation and treatment response to sulfonylureas.
The largest effect on sulfonylurea response reported to date re-
lates to genetic variation in the PK of sulfonylureas, rather than the 
pharmacodynamics. Sulfonylureas are metabolized to an inactive 
form, in large part by cytochrome P450 (CYP) 2C9. Functional 
and PK studies have established that the *2 and *3 alleles are asso-
ciated with reduced function of CYP2C9 and reduced clearance 
of glibenclamide,38 tolbutamide,39 glimepiride,40 and gliclazide 
MR.41 In 1,073 incident users of sulfonylureas (>90% gliclazide) 
in the GoDARTS study, the 8% of the population carrying two 
reduced function alleles at CYP2C9 (*2 or *3) were 3.4- fold more 
likely to achieve therapeutic target than those carrying two nor-
mal function alleles; this equates to a 0.5% difference in HbA1c. 
Similar increased sulfonylurea efficacy was seen for tolbutamide 
in the Rotterdam study,42 where lower tolbutamide dosing was 
required for similar efficacy in those carrying reduced-function 
CYP2C9 alleles. These large effects would certainly suggest that, 
if a patient’s genotype was known, an altered drug initiation dosing 
may be beneficial to achieve similar efficacy at lower doses and thus 
reduce hypoglycemia.
Recently, a further analysis of the GoDARTS study has high-
lighted the role of P450 oxidoreductase (POR), which transfers 
electrons from NADPH to the CYP450 enzymes and is essential 
for normal function of CYP450s.43 In this study, sulfonylurea- 
associated severe hypoglycemia was the end point. There was 
a large increased risk of severe hypoglycemia associated with 
CYP2C9 decreased and nonfunctional variants but only in the 
presence of normal function POR (*1*1) (OR 2.81 (1.30–6.09), 
P = 0.009 per number of CYP2C9 decreased-function alleles). 
No effect of decreased function CYP2C9 alleles was seen in the 
presence of the *28 allele of POR, which is reported to increase 
CYP2C9-mediated activity, thus potentially compensating for 
decreased function of CYP2C9. Whilst there was no analogous 
effect on efficacy, assessed by HbA1c reduction, when dose of 
sulfonylurea was taken into account in a composite endpoint, 
the decreased function CYP2C9 alleles were associated with 
greater efficacy but only on the POR*1*1 background. This 
study highlights the complexity of pharmacogenetic studies 
and how analyzing one gene in isolation can be overly simplis-
tic—e.g., the impact of CYP variants will be likely to rely on 
appropriate transport of sulfonylurea into the liver; and impact 
of pharmacodynamic variants such as TCF7L2 or the KCNJ11/
ABCC8 variants may be masked if CYP activity is not taken into 
account.
Finally, despite being widely used, unlike metformin there has 
not yet been GWASs reported for sulfonylureas. These could shed 
novel insight into the PK and PD of sulfonylureas and are eagerly 
awaited.
THIAZOLIDINEDIONE EFFICACY
Thiazolidinediones (TZDs), often referred to as glitazones, are 
PPARγ agonists. They are potent insulin- sensitizing drugs that 
primarily work on adipose to promote differentiation from pre- 
adipocytes to adipocytes. Pharmacogenetic studies are limited 
and have focused on PK of the TZDs and variation in the key tar-
get gene PPARγ.
As for sulfonylureas, the largest effects are seen for variants al-
tering PK of the TZDs. Hepatic uptake of TZDs is mediated by 
OAT1B1 with metabolism mostly by CYP2C8. These were eval-
uated together in a moderate- sized observational study, again in 
the GoDARTS cohort;44 833 patients were identified who started 
TZD, of whom 273 were treated with pioglitazone and 519 with 
rosiglitazone. For those treated with rosiglitazone, those carrying 
the increased function CYP2C8*3 allele had less HbA1c reduction 
than wild type (allelic β = −0.21%, P = 0.01) and experienced less 
weight gain (allelic β = −0.93 kg, P = 0.02). The SLCO1B1 521C 
(rs4149056) variant was associated with greater HbA1c reduction 
(allelic β = 0.18%, P = 0.04), but not weight gain, after rosiglita-
zone treatment.44 When the two variants were considered together, 
the patients who had reduced transport of OAT1B1 and normal 
metabolism of CYP2C8 had a 0.39% (4 mmol/mol; P = 0.006) 
greater HbA1c reduction than the poor responders.44 Interestingly, 
no effect of these variants was seen with pioglitazone—this is likely 
to reflect the fact that, in contrast to rosiglitazone, pioglitazone 
metabolites are active, so CYP2C8 variants would not be predicted 
to alter response.
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The Pro12Ala (rs1801282) variant in PPARγ was one of the 
first robustly replicated type 2 diabetes risk variants. Given that 
this is the target gene of thiazolidinediones, it is a strong candidate 
for altered glycemic response to TZDs. However, limited studies 
have reported on this variant. The most robust study reported is 
still small, examining TZD response in 250 Chinese patients. 
Compared with wild-type individuals, the 104 carriers of the 
minor allele had an OR 2.32 ((95% CI = 1.10–4.87) P = 0.03) of 
being a responder.45 Association of the same variant with a linear 
reduction in HbA1c and fasting plasma glucose after pioglitazone 
therapy was replicated in an independent cohort of 67 patients.46 
A similar trend was reported in 198 Korean patients treated with 
4 mg rosiglitazone daily for 3 months.47
DPP- 4 INHIBITOR EFFICACY
The only robust study for the DPP- 4 inhibitors identified that a 
variant (rs7202877) near the chymotrypsinogen B1/2 (CTRB1/2) 
gene was associated with glycemic response to DPP- 4 inhibitors. 
Here the initial signal identified the genetic variant to be asso-
ciated with glucagon- like peptide- 1–induced insulin secretion. 
CTRB1/2 encodes chymotrypsin, and the rs7202877G allele 
was associated with an increased fecal chymotrypsin activity. A 
follow- up investigation identified the same variant to be associated 
with HbA1c reduction in 49 patients from the Netherlands and 
305 patients from GoDARTS: Carriers of the rs7202877G allele 
showed 0.51 ± 0.16% lower HbA1c reduction compared with the 
rs7202877 TT genotype (P = 0.0015) after being on gliptins for 
at least 3 months.48
FUTURE STUDIES OF PHARMACOGENETICS IN DIABETES
Like the rest of the genetics community, there is increasing inter-
national collaboration resulting in increasing numbers of patient 
data available for pharmacogenetic studies. To date, these have 
been largely based upon observational studies based upon record 
linkage, but pharmaceutical companies are increasingly making 
their trial data available and are more routinely incorporating 
genetic studies into their trial protocols. This will result in in-
creasing opportunity—not only for discovery of genetic variants 
associated with response but also to evaluate drug side effects (e.g., 
nausea with GLP1RA or edema with thiazolidinediones) and 
other nonglycemic outcomes such as cardiovascular risk. Another 
emerging area where we may potentially see larger effect sizes for 
drug efficacy in diabetes comes from the increasing use of poly-
genic risk scores. There are now 400 variants for type 2 diabetes 
now identified, which when summed as a polygenic risk score 
can explain large differences in risk.49 For example, the top and 
bottom 2.5% of the distribution differ in risk of diabetes by ~ 10- 
fold. These 400 variants can be grouped together according to the 
pathophysiological process they affect into what have been termed 
process- specific polygenic risk scores, e.g., those affecting beta- cell 
function, or fat distribution.49,50 These have modest effects on 
the underlying trait, and as diabetes drugs act on these particular 
traits, one would hope that these process- specific polygenic risk 
scores will have moderate impact on glycemic response to diabetes 
drugs.
CONCLUSIONS
In current clinical practice, genetic etiology of diabetes has been 
shown to have a big impact on treatment response in the small 
group of patients who have monogenic diabetes, and for these 
patients finding the genetic etiology can be life- changing—
transitioning successfully off insulin onto sulfonylurea treat-
ment. However, for common complex diseases such as type 
2 diabetes, it is unlikely that large-effect etiological variants 
will be identified due to the genetic architecture of these dis-
eases being driven largely by multiple small effect variants. 
Whilst a number of robust genetic variants have been estab-
lished to be associated with glycemic response to metformin, 
Figure 4 The future role of pharmacogenetics in type 2 diabetes—a summary of the robust and clinically relevant drug–gene interactions 
that will be of likely clinical utility but only when a preemptive genotyping approach is adopted. CYP, cytochrome P450; DPP- 4, dipeptidyl 
peptidase- 4; HbA1c, hemoglobin A1c; OR, odds ratio; OCT1, organic cation transporter 1; PMAT, plasma membrane monoamine transporter; 
SU, sulfonylurea; T2DM, type 2 diabetes mellitus; TZDs, thiazolidinediones.
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sulfonylureas, thiazolidinediones, and DPP- 4 inhibitors, sum-
marized in Figure 4, these effects are not large enough to jus-
tify genetic testing before deciding on treatment—the delay, 
cost, and limited predictive utility make this impractical and 
not cost- effective. However, with the costs of genotyping plat-
forms now as low as £30, a threshold has been reached where 
preemptive genotyping can (and should) be undertaken, with 
results embedded in the medical record. At this point, if the 
choice of second- line or third- line therapies is at equipoise, and 
the genetic information is already available, then these genetic 
factors can be used to aid in prescribing choice. In order for use 
of preemptive genotyping for all to become reality, focus now 
needs to be on processes to facilitate this. For example, mapping 
from genotype to clinical recommendation will be a dynamic 
process, as novel pharmacogenetic findings are identified; given 
this, it will probably be best to hold the genetic and mapping 
information centrally (within the National Health Service or 
healthcare provider) to be queried at the point of prescribing 
by primary or secondary care clinical decision support tools. 
However, to answer the question posed in the title of the review, 
I am in no doubt that pharmacogenetics will become main-
stream in the management of diabetes—not only monogenic 
diabetes but also in type 2 diabetes.
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